- Home
- PMCB vs DPRO Comparison
PMCB vs DPRO Comparison
Compare PMCB & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- DPRO
- Stock Information
- Founded
- PMCB 1996
- DPRO 1998
- Country
- PMCB United States
- DPRO Canada
- Employees
- PMCB N/A
- DPRO N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- DPRO Aerospace
- Sector
- PMCB Health Care
- DPRO Industrials
- Exchange
- PMCB Nasdaq
- DPRO Nasdaq
- Market Cap
- PMCB 11.4M
- DPRO 13.0M
- IPO Year
- PMCB N/A
- DPRO N/A
- Fundamental
- Price
- PMCB $1.19
- DPRO $2.61
- Analyst Decision
- PMCB
- DPRO Strong Buy
- Analyst Count
- PMCB 0
- DPRO 2
- Target Price
- PMCB N/A
- DPRO $7.00
- AVG Volume (30 Days)
- PMCB 17.9K
- DPRO 91.1K
- Earning Date
- PMCB 03-17-2025
- DPRO 05-13-2025
- Dividend Yield
- PMCB N/A
- DPRO N/A
- EPS Growth
- PMCB N/A
- DPRO N/A
- EPS
- PMCB 1.29
- DPRO N/A
- Revenue
- PMCB N/A
- DPRO $4,559,961.00
- Revenue This Year
- PMCB N/A
- DPRO $146.64
- Revenue Next Year
- PMCB N/A
- DPRO $71.45
- P/E Ratio
- PMCB $0.89
- DPRO N/A
- Revenue Growth
- PMCB N/A
- DPRO 0.10
- 52 Week Low
- PMCB $1.05
- DPRO $1.55
- 52 Week High
- PMCB $2.42
- DPRO $9.13
- Technical
- Relative Strength Index (RSI)
- PMCB 39.44
- DPRO 51.57
- Support Level
- PMCB $1.05
- DPRO $2.07
- Resistance Level
- PMCB $1.27
- DPRO $2.70
- Average True Range (ATR)
- PMCB 0.12
- DPRO 0.28
- MACD
- PMCB 0.00
- DPRO 0.04
- Stochastic Oscillator
- PMCB 37.21
- DPRO 82.10
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.